Form 4: Marillyn Hewson Acquires JNJ Deferred Share Units
Statement of Changes in Beneficial Ownership
Director Marillyn A. Hewson acquired 975 deferred share units as part of the Johnson & Johnson director compensation plan.
Summary
- Director Marillyn A. Hewson was granted 975 deferred share units (DSUs) on April 23, 2026.
- The DSUs were acquired under the Johnson & Johnson Amended and Restated Deferred Fee Plan for Directors.
- These units are to be settled in cash upon the termination of the reporting person's directorship.
- Following this transaction, the reporting person holds a total of 15,487.939 deferred share units.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial outlook.
Positives
- Demonstrates continued alignment between director interests and company performance through equity-based compensation.
Negatives
- None identified.
Risks
- Value of deferred share units is tied to the future market performance of Johnson & Johnson common stock.
Future Outlook
The deferred share units will be settled in cash upon the termination of the reporting person's directorship, with the value determined by the fair market value of common stock at that time.
Industry Context
StockSavvy.ai notes that this is a routine disclosure of director compensation, consistent with standard corporate governance practices for large-cap pharmaceutical companies where directors receive a portion of their fees in equity-linked instruments to ensure long-term alignment with shareholders.
Comparison to Industry Standards
- The use of deferred share units for director compensation is a standard practice among S&P 500 companies, including peers like Pfizer and Merck.
- The structure of the compensation plan aligns with typical governance benchmarks for non-employee director remuneration.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of deferred share units under the Amended and Restated Deferred Fee Plan for Directors. | 2026-04-23 | Standard alignment of director interests with shareholder value. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard component of director compensation packages.
Next Steps
- No further action required by the reporting person regarding this specific transaction.
Key Dates
| Date | Description |
|---|---|
| 2025-12-09 | Date of Power of Attorney execution. |
| 2026-04-23 | Date of the reported transaction (grant of DSUs). |
| 2026-04-27 | Date of filing. |
Keywords
Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.